Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma. As of December 2011 , it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity.
This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.
In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP). A phase II trial is planned to run for 5 years.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
- ^ Rossi, E. A.; Goldenberg, D. M.; Cardillo, T. M.; Stein, R.; Chang, C. -H. (2009). "CD20-targeted tetrameric interferon- , a novel and potent immunocytokine for the therapy of B-cell lymphomas". Blood. 114 (18): 3864–71. doi:10.1182/blood-2009-06-228890. PMC 2773491. PMID 19710501.
- ^ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
- ^ Christian, BA; Poi, M; Jones, JA; Porcu, P; Maddocks, K; Flynn, JM; Benson, DM Jr; Phelps, MA; Wei, L; Byrd, JC; Wegener, WA; Goldenberg, DM; Baiocchi, RA; Blum, KA (2015). "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma". Br J Haematol. 169 (5): 701–10. doi:10.1111/bjh.13354. PMID 25847298.
- ^ Handbook of Therapeutic Antibodies. p791
- ^ a b FDA grants orphan drug designation to veltuzumab for ITP